Durect — Investor Presentation (May 2023)
53 slides from Durect's investor presentation, May 16, 2023
Slide 1: Key Opinion Leader Discussion: Larsucosterol & Alcohol-associated Hepatitis
Key Opinion Leader Discussion: Larsucosterol & Alcohol-associated Hepatitis May 16th, 2023
Slide 2: Agenda
Agenda Introduction / Welcome Jim Brown, DVM What is AH? Paul Gaglio, MD Larsucosterol: Addressing the AH Treatment Gap Brett Fortune, MD Larsucosterol and the Phase 2b AHFIRM Trial Norman Sussman, MD Larsucosterol Commercial Opportunity Keith Lui Q&A 2
Slide 3: Disclaimer
Disclaimer This presentation and various remarks we make during this presentation contain forward-looking statements of DURECT Corporation ("DURECT," the "Company," "we," "our" or "us") and its collaborative partners within the meaning of applicable securities laws and regulations, which are subject
Slide 4: Introduction
Introduction Jim Brown, DVM President and Chief Executive Officer
Slide 5: Harnessing the Power of Epigenetics
Harnessing the Power of Epigenetics Epigenetics focuses on altering gene expression without changing DNA sequences These changes can be inherited and/or environmental Disease states can change epigenetics Epigenetic changes can manifest as disease Examples of such changes are DNA methylation and his
Slide 6: Larsucosterol Overview
Larsucosterol Overview Lead Compound in DURECT’s Epigenetic Modulator Program Modulator of DNA methylation Clinical safety Role in cellular functions Broad therapeutic potential New class of therapeutics Endogenous sulfated oxysterol Highly conserved across all 7 species studied to date Stabilizes m
Slide 7: Larsucosterol Has Been Studied in Broad Range of Indications
Larsucosterol Has Been Studied in Broad Range of Indications Compelling data in all animal models Acute Pancreatitis Rat Acute Organ Injury Models Acetaminophen / Alcohol Injury Mouse Endotoxin Injury Mouse Brain Ischemic Injury Rat Renal Ischemic Injury Rat STAM™ NASH Chronic Disease Models High Fa
Slide 8: Mechanism of Action Leverages Epigenetics to Impact Disease
Mechanism of Action Leverages Epigenetics to Impact Disease Epigenetic Dysregulation in AH Patients Aberrant DNA hypermethylation is associated with many diseases including severe AH Epigenetic Regulators Modulate Gene Expression DNA methyltransferases (DNMTs) are one such regulator that add methyl
Slide 9: Inhibition of DNMT-1, 3a & 3b Aligns with AH
Inhibition of DNMT-1, 3a & 3b Aligns with AH Liver samples from patients with severe AH have increased expression of DNMT-1 & 3a Wang Y et al. 2021, Journal of Lipid Research, 62:1-14 Note: in this paper, larsucosterol is referred to as 25HC3S Argemi et al. 2019. Nature Communications, 10: 3126
Slide 10: What Is AH?
What Is AH? Paul Gaglio, MD Director of Hepatology Outreach, Columbia
Slide 11: Dr. Paul J. Gaglio: Biography and Disclosures
Dr. Paul J. Gaglio: Biography and Disclosures Paul J. Gaglio, MD, FACP, AGAF, FAASLD, Professor of Medicine (in Surgery) Director of Hepatology Outreach at NY-Presbyterian Hospital, Columbia University Irving Medical Center Former Medical Director of Adult Liver Transplantation at the Montefiore Med
Slide 12: What Is AH?
What Is AH? A typical patient with alcohol-associated hepatitis (AH) What is excessive drinking? AH is usually associated with very heavy drinking AH as a distinct clinical entity with a high mortality Multiple causes of death including sepsis and liver failure Methods of assessing AH severity Curre
Slide 13: Case Presentation – A Sample Patient Journey
Case Presentation – A Sample Patient Journey 40 year old man, transferred from an outside hospital with jaundice and concern for liver failure Past medical history includes type 2 DM, hyperlipidemia, BMI 31 Labs at transfer: MELD 29 (Model for End-stage Liver Disease) Lives with his wife and three c
Slide 14: Higher MELD Scores Correlate with Increased Mortality
Higher MELD Scores Correlate with Increased Mortality MayoClinic.org INR – blood clotting Factors are made by the liver Bilirubin – yellow pigment derived from red blood cells Causes jaundice Creatinine – measure of kidney function Components of MELD Score Expected 90-day mortality: 45-58% 14
Slide 15: NIAAA Definitions for Adults of Drinking Age
NIAAA Definitions for Adults of Drinking Age Moderate Men: 2/day (<14/week) Women: 1/day (<7/week) Heavy Men: 4/day or >14/week Women: 3/day or >7/week Binge: Blood alcohol >0.08% Men: >5 drinks in ~2 hours Women: >4 drinks in ~2 hours Asgaard, G et al. J Hep 2015; 62:1061-1067
Slide 16: Alcohol Sales and Alcohol-Related Deaths Rising Steadily
Alcohol Sales and Alcohol-Related Deaths Rising Steadily Exacerbated by Covid/Quarantine Anderson MS, et al. JAMA Open 2021 National monthly retail alcohol sales 2016-2021 for purchases from beer, wine, and liquor stores from the US Census Bureau Monthly Retail Trade Report Males Females Jan 2020 De
Slide 17: AH is a Detour
AH is a Detour Normal Liver Fatty Liver Increasing Fibrosis Cirrhosis Decompensated Cirrhosis Death Liver Transplant Alcohol Alcohol Alcohol Steatohepatitis Severe AH Mild-Moderate AH Death Liver Transplant Typical ALD Pathway AH Detour
Slide 18: AH is Associated with Heavy Drinking and a Serious Risk of Death
AH is Associated with Heavy Drinking and a Serious Risk of Death Thursz M et al. N Engl J Med 2015; 372:1619-28 Age 49 yrs Maddrey 63 Male 60% MELD 21 EtOH (F) 150 g/day GAHS 8.4 EtOH (M) 200 g/day Mortality (28/90) 16%/30% 18
Slide 19: Alcohol is Currently the Leading Cause for Liver Transplantation
Alcohol is Currently the Leading Cause for Liver Transplantation Kwong AJ et al. OPTN/SRTR Annual Data Report, 2021 19 3,249 Transplant Listing by Diagnosis Liver Transplants by Diagnosis ~8,700 adult liver transplants in 2021 Insufficient to meet patient needs
Slide 20: Case Presentation – Patient Journey (continued)
Case Presentation – Patient Journey (continued) Blood and urine cultures negative at time of admissions CXR was normal Patient was eligible for prednisolone Started prednisolone, B-vitamins, zinc, and nutrition Lille score at day 4 did not improve – stopped prednisolone Presented to our multidiscipl
Slide 21: Lille Score at Day-4 Predicts AH Survival
Lille Score at Day-4 Predicts AH Survival at 6 Months Based primarily on declining bilirubin Garcia-Saenz-de-Sicilia et al. Am J Gastroenterol 2017; 112:306-315 Age Bilirubin Day 0 Albumin Day 0 Creatinine Day 0 Protime Day 0 Bilirubin Day 4 Years mg/dL g/dL mg/dL sec mg/dL LM = Lille Model (LM) at
Slide 22: Conclusions
Conclusions AH is a detour from usual alcohol-associated liver disease AH usually occurs in very heavy drinkers MELD and Lille scores predict risk of death 30-50% mortality in severe cases of AH Steroids may be used in severe cases Frequently contraindicated Not FDA-approved No effect on survival at
Slide 23: Larsucosterol: Addressing the AH Treatment Gap
Larsucosterol: Addressing the AH Treatment Gap Brett Fortune, MD Montefiore Medical Center
Slide 24: Dr. Brett Fortune: Biography and Disclosures
Dr. Brett Fortune: Biography and Disclosures Brett E. Fortune, MD, MSc, FAASLD, Associate Professor of Medicine Associate Professor of Medicine at Albert Einstein College of Medicine Medical Director, Liver Transplant Program at Montefiore Einstein Center for Transplantation Associate Editor of Live
Slide 25: Current State of AH Treatment Options
Current State of AH Treatment Options AH is potentially survivable Need a therapeutic agent that improves odds for patients Steroids are controversial Many contraindications and no long-term benefit Transplants benefit patients Many patients are not eligible Availability insufficient for qualified p
Slide 26: Lille Score – Predicts AH Survival
Lille Score – Predicts AH Survival at 6 Months Based primarily on declining bilirubin day 0-7 Louvet A et al. Hepatology 2007; 45:1348-1354 Age Bilirubin Day 0 Albumin Day 0 Creatinine Day 0 Protime Day 0 Bilirubin Day 7 Years mg/dL g/dL mg/dL sec mg/dL
Slide 27: Decreasing Bilirubin Predicts AH Survival Irrespective of Steroids
Decreasing Bilirubin Predicts AH Survival Irrespective of Steroids Parker R et al. Clin Gastro Hepatol (2022); 20:e289–e297
Slide 28: Would an Effective Therapeutic Help with AH Management?
Would an Effective Therapeutic Help with AH Management?
Slide 29: Transplant Is Not an Option for Most Severe AH Patients
Transplant Is Not an Option for Most Severe AH (SAH) Patients Only a minority respond to current SAH therapy For nonresponders: Very few patients make it to liver transplant Only 16% were wait listed for transplant Likely overestimates transplant access Im G, et al. Liver Transplantation 2022 Early
Slide 30: Nonresponding Patients Declined for Transplant Have High Mortality
Nonresponding Patients Declined for Transplant Are Unlikely to Regain Normal Liver Function and Have High Mortality 49% died after 6 months, only 10% had recompensation at 1 year Hsu C, et al. ACCELERATE-AH group. Hepatology 2023
Slide 31: Would We Like an Effective SAH Therapeutic? – YES!!!
Would We Like an Effective SAH Therapeutic? – YES!!! SAH is a potentially survivable condition but lacks an effective treatment Among nonresponders, liver transplant is the only curative option but rarely available to SAH patients An effective treatment for SAH would: Improve short-term and (ideally
Slide 32: Phase 2a: Evaluation of Larsucosterol in Moderate/Severe AH
Phase 2a: Evaluation of Larsucosterol in Patients with Moderate/Severe Alcohol-Associated Hepatitis Key Inclusion Criteria Study Design Endpoints Moderate AH: MELD 11-20 Severe AH: MELD 21-30 Screening Follow up Larsucosterol 150 mg Larsucosterol 90 mg Larsucosterol 30 mg Day -4 Day 1 Day 4 Day 28 D
Slide 33: Larsucosterol: Summary of Phase 2a Trial in AH
Larsucosterol: Summary of Phase 2a Trial in AH Improved key biomarkers and prognostic indicators Reduced bilirubin and MELD scores 89% response rate based on Lille score Well tolerated across all dose levels with no drug-related SAEs 100% Survival (19/19) in Open Label Phase 2a Trial in Patients wit
Slide 34: Phase 2a: Majority of Patients Discharged After One Dose
Phase 2a: Majority of Patients Discharged After One Dose Potential Pharmacoeconomic Benefit as Measured by Time to Discharge Number (%) of patients who were discharged in ≤ 4 days after receiving a single dose of larsucosterol All patients (n=19) 14/19 (74%) Severe patients (MELD 21-30) (n=12) 8/12
Slide 35: Phase 2a: Reduction in Bilirubin & MELD
Phase 2a: Reduction in Bilirubin & MELD More Pronounced Effect in Patients with Higher Bilirubin One of 19 patients did not return for the follow-up visits on Day 7 and Day 28; all data were analyzed based on those who completed visits.
Slide 36: Lille Score – The Best Early Predictor of Survival
Lille Score – The Best Early Predictor of Survival Larsucosterol Subjects had Lower Lille Scores – Best for 30 & 90 mg Doses Hassanein T et al. Am J Gastro (in press) 30 & 90 mg doses ** Represents p<0.01 by T-test; Non-head-to-head comparison
Slide 37: Summary
Summary All subjects in the larsucosterol arms survived 30 & 90 mg are in the optimal therapeutic range 150 mg may be outside the optimal range Biochemical and clinical outcomes support further development of this drug A randomized, double-blind, placebo-control trial (AHFIRM) is in progress
Slide 38: Larsucosterol and the Phase 2b AHFIRM trial
Larsucosterol and the Phase 2b AHFIRM trial Norman L. Sussman, MD, FAASLD Chief Medical Officer
Slide 39: What We Know About AH
What We Know About AH A serious acute disease with a high risk of death Average 30% mortality at 90 days Incidence was increasing prior to the COVID-19 pandemic Trend exacerbated at the time of lock-down The demographic is shifting to younger patients and a higher percentage of women No satisfactory
Slide 40: Histologic Changes in Alcohol Associated Liver Disease
Histologic Changes in Alcohol Associated Liver Disease Normal AH ALD
Slide 41: Larsucosterol Clinical Progress
Larsucosterol Clinical Progress Phase 2a provided the impetus for a randomized, placebo-control trial Improved biochemical profile 100% survival Phase 2b AHFIRM: Subjects with Alcoholic Hepatitis to Evaluate SaFety EffIcacy of LaRsucosterol TreatMent Key differences from Phase 2a Restricted to SAH p
Slide 42: AHFIRM – Larsucosterol Phase 2b Trial for AH
Key Inclusion Criteria Study Design Severe AH: MDF > 32, MELD 21-30 300 subjects randomized 1:1:1 into two treatment groups vs. SoC Screening Follow up Larsucosterol 90 mg Larsucosterol 30 mg Placebo Day -4 Day 1 Day 4 Day 90 Dose 1 (IV Infusion) Dose 2 (if not discharged) Multinational US, EU, UK,
Slide 43: AHFIRM – Larsucosterol Phase 2b Trial for AH: Endpoints
AHFIRM – Larsucosterol Phase 2b Trial for AH Key Secondary Endpoints 90-day mortality 28-day event rate (death or liver transplantation) 28-day mortality Primary Endpoint 90-day event rate (death or liver transplantation)
Slide 44: AHFIRM Trial – Anticipated Next Steps
AHFIRM Trial – Anticipated Next Steps Completion of Enrollment (2Q23) Last Patient Visit ~90 days following completion of enrollment (3Q23) Top-Line Results ~8-12 weeks following last patient visit (4Q23) Initial results for primary and key secondary endpoints Potential NDA filing following positive
Slide 45: Larsucosterol Commercial Opportunity
Larsucosterol Commercial Opportunity Keith Lui SVP, BD, Commercial, Medical Affairs
Slide 46: AH Imposes High Economic Burden on US Healthcare System
AH Imposes High Economic Burden on US Healthcare System ~158,000 U.S. hospitalizations per year1 AH hospitalizations increased by approximately 5.5% per year between 2015 and 20192 86% of hospitalized AH patients are insured2 1 https://www.hcup-us.ahrq.gov/db/nation/nis/nisdbdocumentation.jsp 2 Marl
Slide 47: Primary Research with Multiple Hospital Stakeholders Informs AH Market Landscape
Primary Research with Multiple Hospital Stakeholders Informs AH Market Landscape, Strategy and Access Considerations 47 Defined Terms: KOL: Key Opinion Leader; MCO: Managed Care Organization; DRG: Diagnosis-related Group; P&T: Pharmacy & Therapeutics. Academic and community board-certified KOLs, hos
Slide 48: High Unmet Needs for AH Included the Need for More Effective Therapies
High Unmet Needs for AH Included the Need for More Effective Therapies That Reduce Mortality and Reducing Continual Alcohol Use 48 Unmet Need Physician Perspectives Description Degree of Need Preventing Alcohol Use Post-discharge “We need something which can reduce long-term mortality, steroids are
Slide 49: Value Drivers Differed Across Stakeholders
Value Drivers Differed Across Stakeholders, Highlighting Importance of Tailored Framing of Larsucosterol Value Proposition Stakeholder Interviews; ClearView Analysis. Hospital Cost Offset Economics Reduction in Healthcare System Cost Burden Reduction in Mortality Physicians prioritize mortality as t
Slide 50: Larsucosterol AH Launch Strategic Imperatives and Goals
Larsucosterol AH Launch Strategic Imperatives (SI) and Goals SI1 SI2 SI3 SI4 Launch Goals Establish larsucosterol as the revolutionary advancement in the treatment of AH Ensure early and comprehensive access through bold regulatory, clinical, and value / access strategies Create a tailored, comprehe
Slide 51: Larsucosterol Launch Preparation and Commercial Infrastructure Development Are Underway
Larsucosterol Launch Preparation and Commercial Infrastructure Development Are Underway Early planning allows time to build capabilities and mitigate risks and delays, while being mindful of other organizational priorities 2023 Launch Readiness Objectives Key Initiatives Ongoing Understand needs and
Slide 52: Thank You!
ff “4 Thank You! durect
Slide 53: Q&A
Q&A